Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
暂无分享,去创建一个
M. Konopleva | M. Andreeff | H. Kantarjian | G. Garcia-Manero | K. Patel | T. Kadia | F. Ravandi | Koichi Takahashi | N. Daver | C. Dinardo | R. Kanagal-Shamanna | J. Ning | N. Short | G. Montalban-Bravo | H. Hwang | M. Franquiz | G. Issa
[1] M. Konopleva,et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. , 2020, Blood advances.
[2] Qi Zhang,et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.
[3] A. Berghold,et al. Functional Classification of TP53 Mutations in Acute Myeloid Leukemia , 2019, Cancers.
[4] H. Kantarjian,et al. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.
[5] Jiqiang Yao,et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) , 2019, Blood.
[6] P. Vyas,et al. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results , 2019, Blood.
[7] M. Konopleva,et al. Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. , 2019, Journal of Clinical Oncology.
[8] Eric R. Wolf,et al. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway , 2019, Nature Communications.
[9] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[10] M. Konopleva,et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. , 2019, The Lancet. Haematology.
[11] A. Berghold,et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia , 2018, Haematologica.
[12] L. Bullinger,et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care , 2018, Leukemia.
[13] J. Cortes,et al. Acute myeloid leukaemia , 2018, The Lancet.
[14] K. Patel,et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. , 2018, Blood.
[15] M. Konopleva,et al. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia , 2018, American journal of hematology.
[16] Molecular predictors of post-transplant survival in acute myeloid leukemia , 2017, Blood Cancer Journal.
[17] M. Konopleva,et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. , 2017, Blood advances.
[18] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[19] Thomas Efferth,et al. The role of p53 in cancer drug resistance and targeted chemotherapy , 2016, Oncotarget.
[20] Christopher A. Miller,et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.
[21] Rashmi Kanagal-Shamanna,et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes , 2016, Cancer.
[22] R. Bellazzi,et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Maciejewski,et al. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort , 2016, Leukemia.
[24] N. Schmitz,et al. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[26] L. Bullinger,et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.
[27] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[29] J. Esteve,et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.
[30] G. Juliusson,et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[32] R. Hills,et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis , 2009, Leukemia.